WG5 of COST ANIRIDIA CA18116

menu

WORK GROUP 5 TASKS

Image from: Kirsten Goetz, BS, Jesse M. Vislisel, MD, Matthew E. Raecker, MD, Kenneth M. Goins, MD
Image from: Kirsten Goetz, BS, Jesse M. Vislisel, MD, Matthew E. Raecker, MD, Kenneth M. Goins, MD

Action Title: Aniridia: networking to address an unmet medical, scientific, and societal challenge


WG5: (Leader: Daniel Aberdam, F) (co-leader: Huiqing (Jo) Zhou, NL)

To identify and validate new therapeutic tools to treat aniridia-associated keratopathy (AAK), limbal stem cell deficiency and dry eye, WG5 will list among the COST Aniridia members the different cellular and animal models as well as imaging technology in animals that could be relevant for the disease treatment. This includes primary patient cells, genome editing/siRNA and patient-derived iPSC, as well as 3D culture and bioengineering. OMICS analyses will clarify the nature and defects of the different cellular models. These tools will serve to screen for drugs and other alternative therapeutic tools. These efforts will be a great opportunity for collaboration between partners.


For the WG5 participants, please click the link to add/modify any information that could be shared.